Clinical Trial Update: A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update for TAK-279 in adults with Generalized Pustular Psoriasis or Erythrodermic Psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Generalized Pustular Psoriasis

Drugs mentioned

• TAK-279

Snippet

Sponsor: Takeda | Conditions: Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Status: COMPLETED